Clinical characteristics and molecular heterogeneity in Follicular lymphoma with extranodal involvement.

ABSTRACT:

Background

Follicular lymphoma (FL) represents the most common subtype of indolent non-Hodgkin's lymphoma. Extranodal involvement (ENI) indicates a poor clinical outcome in patients who received rituximab-based immunochemotherapy. Recent studies indicate that genetic alterations and tumor microenvironment dysregulation drive extranodal dissemination and lymphoma progression. However, the molecular mechanisms underlying ENI in FL remain to be fully elucidated.

Methods

Aiming to investigate the influence of oncogenic mutations and tumor microenvironment alterations on ENI in FL, the clinical features of 501 patients with newly diagnosed FL receiving rituximab-based therapy were analyzed, with DNA and RNA sequencing performed on 403 and 175 patients, respectively.

Results

SUBMITTER: Li RC 

PROVIDER: S-EPMC12553287 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature